| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LPCAT3 |
| Uniprot No | Q6P1A2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-487aa |
| 氨基酸序列 | MASSAEGDEGTVVALAGVLQSGFQELSLNKLATSLGASEQALRLIISIFLGYPFALFYRHYLFYKETYLIHLFHTFTGLSIAYFNFGNQLYHSLLCIVLQFLILRLMGRTITAVLTTFCFQMAYLLAGYYYTATGNYDIKWTMPHCVLTLKLIGLAVDYFDGGKDQNSLSSEQQKYAIRGVPSLLEVAGFSYFYGAFLVGPQFSMNHYMKLVQGELIDIPGKIPNSIIPALKRLSLGLFYLVGYTLLSPHITEDYLLTEDYDNHPFWFRCMYMLIWGKFVLYKYVTCWLVTEGVCILTGLGFNGFEEKGKAKWDACANMKVWLFETNPRFTGTIASFNINTNAWVARYIFKRLKFLGNKELSQGLSLLFLALWHGLHSGYLVCFQMEFLIVIVERQAARLIQESPTLSKLAAITVLQPFYYLVQQTIHWLFMGYSMTAFCLFTWDKWLKVYKSIYFLGHIFFLSLLFILPYIHKAMVPRKEKLKKME |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LPCAT3重组蛋白的3条参考文献及其摘要概括：
1. **"LPCAT3 deficiency disrupts phospholipid composition and cholesterol metabolism in mouse liver"**
- **作者**: Rong et al. (2015)
- **摘要**: 研究发现LPCAT3通过调控溶血磷脂酰胆碱酰基转移酶活性，影响肝细胞膜磷脂组成，其缺失导致肝脏胆固醇积累和脂代谢紊乱，加剧非酒精性脂肪肝的发展。
2. **"LPCAT3-dependent phospholipid remodeling regulates mitochondrial energy metabolism and protects against steatohepatitis"**
- **作者**: Li et al. (2020)
- **摘要**: 该文献揭示LPCAT3通过重塑线粒体膜磷脂组成(如心磷脂合成)，维持线粒体功能，其表达下调与肝脏炎症和纤维化相关，为代谢综合征提供分子机制解释。
3. **"Intestinal LPCAT3 deficiency attenuates dietary fat absorption and protects against diet-induced obesity"**
- **作者**: Wang et al. (2018)
- **摘要**: 研究证明肠道中LPCAT3通过促进磷脂酰胆碱的合成，调控乳糜微粒形成和脂质吸收，其敲除可减少高脂饮食诱导的肥胖和胰岛素抵抗。
LPCAT3 (lysophosphatidylcholine acyltransferase 3) is a key enzyme in phospholipid remodeling, part of the Lands cycle that maintains membrane lipid diversity. It catalyzes the acylation of lysophosphatidylcholine (LPC) to form phosphatidylcholine (PC), a major structural component of cellular membranes. This enzyme preferentially incorporates polyunsaturated fatty acids (PUFAs), particularly arachidonic acid (AA) and linoleic acid, into the *sn-2* position of PC, influencing membrane fluidity, signaling, and lipoprotein assembly.
Expressed predominantly in metabolic tissues like liver, intestine, and adipose tissue, LPCAT3 plays critical roles in lipid homeostasis. It regulates very-low-density lipoprotein (VLDL) secretion in hepatocytes and dietary lipid absorption in enterocytes. Studies link its activity to metabolic disorders, including non-alcoholic fatty liver disease (NAFLD) and atherosclerosis, through its impact on lipid droplet dynamics and endoplasmic reticulum (ER) membrane integrity.
Recombinant LPCAT3 protein is produced via heterologous expression systems (e.g., E. coli, mammalian cells) for functional studies. Its purified form enables in vitro analysis of enzymatic kinetics, substrate specificity, and inhibitor screening. Researchers utilize it to explore mechanisms of lipid-induced ER stress, inflammation, and metabolic syndrome. Structural studies aim to resolve its catalytic domains and regulatory motifs, offering insights for therapeutic targeting.
Dysregulation of LPCAT3 is associated with altered PUFA-PC levels, affecting the production of lipid mediators like eicosanoids. Recent work highlights its dual role in both promoting hepatic steatosis and protecting against oxidative stress, making it a nuanced target for metabolic disease intervention. The recombinant tool remains vital for dissecting these complex physiological and pathological processes.
×
